Michigan State University

University of California

Babak Borhan

Bruce D Hammock

Jiang Zheng

David F Grant

Mehran F Moghaddam

Jessica F Greene

Marlene F Sisemore

Kin Sing Lee

Jeffrey M Cheek

Kazuhiko Matoba

James Fergusson

Wenjing Wang

Chrysoula Vasileiou

Tetyana Berbasova

James Geiger

Christophe H Morisseau

Richard R Lunt, Iii

James Sanborn

Chenchen Yang

Kazuhiko Motoba

Benjamin G Levine

Jun Zhang

Wei Sheng

Jennifer M Schomaker

Benjamin R Travis

A luminescent solar concentrator (LSC) device is provided. The LSC device has an active layer including a modified luminophore having a polymethine component including a plurality of methine groups (═CH—), where n is an odd integer greater than 1. A hydrogen atom (H) of one of the plurality of methine groups is replaced by one of -ARRor -DR, where A is selected from nitrogen (N), phosphorus (P), arsenic (As) and antimony (Sb) and D is selected from oxygen (O), sulfur (S), selenium (Se), and tellurium (Te), Rand Rare independently selected from H, aliphatic groups, and aromatic groups bound to A through a carbon atom, or Rand Rtogether form an alicyclic ring containing A, and Ris selected from H, aliphatic groups, aromatic groups, and alicyclic groups bound to D through a carbon atom.

Near-infrared harvesting transparent luminescent solar concentrators with engineered stokes shift

The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.

Colorimetric and fluorescent proteins

The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R-Ris hydrogen, Ris hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, Ris hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, Rand Ris each independently C-Csubstituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

Inhibitors of epoxide hydrolases for the treatment of inflammation

An osmium-assisted process for the oxidative cleavage of oxidizable organic compounds such as unsaturated organic compounds, including alkenes and olefins into aldehydes, carboxylic acids, esters, or ketones. The process uses a metal catalyst comprising osmium and a peroxy compound selected from the group consisting of peroxymonosulfuric acid and salts thereof to oxidatively cleave the oxidizable organic compound. In particular, the process enables aldehydes, carboxylic acids, esters, or ketones to be selectively produced from the corresponding mono-, 1,1-di-, 1,2-di-, tri-, or tetra-substituted olefins in a reaction that produces the result of ozonolysis but with fewer problems. The present invention further provides a process for oxidizing an aldehyde alone or with the osmium in an interactive solvent to produce an ester or carboxylic acid.

Catalytic osmium-assisted oxidative cleavage of olefins

The present invention provides methods of treating inflammatory diseases mediated by poly-unsaturated lipid metabolites by inhibiting epoxide hydrolase, methods for assaying or screening the epoxide hydrolase inhibitors for inhibitory specificity and for toxicity, and novel biologically active tetrahydrofuran diols of arachidonic acid, including antibodies thereto.

Epoxide hydrolase inhibitor methods

The present invention provides novel biologically active tetrahydrofuran diols of arachidonic acid.

Dihydroxy-oxy-eicosadienoates

Growing community of inventors

East Lansing, MI, United States of America

Babak Borhan